Janux Therapeutics, Inc. financial data

Symbol
JANX on Nasdaq
Industry
Pharmaceutical Preparations
Location
10955 Vista Sorrento Parkway, Suite 200, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4.46K % +120%
Debt-to-equity 6.13 % -52.3%
Return On Equity -10.5 % +46.5%
Return On Assets -9.86 % +43.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 52.5M shares +13.7%
Common Stock, Shares, Outstanding 52.3M shares +13.4%
Entity Public Float 280M USD +36.5%
Common Stock, Value, Issued 52K USD +13%
Weighted Average Number of Shares Outstanding, Basic 54.6M shares +19.5%
Weighted Average Number of Shares Outstanding, Diluted 54.6M shares +19.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 59.8M USD +2.94%
General and Administrative Expense 39.2M USD +53.9%
Operating Income (Loss) -86M USD -14.5%
Nonoperating Income (Expense) 25.4M USD +103%
Net Income (Loss) Attributable to Parent -60.5M USD +3.3%
Earnings Per Share, Basic -1.15 USD/shares +22.3%
Earnings Per Share, Diluted -1.15 USD/shares +22.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26.8M USD +56%
Accounts Receivable, after Allowance for Credit Loss, Current 7.5M USD
Assets, Current 666M USD +87.6%
Property, Plant and Equipment, Net 5.37M USD -26.6%
Operating Lease, Right-of-Use Asset 19.7M USD -7.18%
Other Assets, Noncurrent 2.82M USD +22%
Assets 695M USD +79.7%
Accounts Payable, Current 2.46M USD -1.72%
Employee-related Liabilities, Current 3.9M USD +62.9%
Accrued Liabilities, Current 13M USD +90.6%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 17.2M USD +18.7%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 21.7M USD -7.21%
Liabilities 38.9M USD +2.67%
Accumulated Other Comprehensive Income (Loss), Net of Tax 7.83M USD
Retained Earnings (Accumulated Deficit) -218M USD -38.6%
Stockholders' Equity Attributable to Parent 656M USD +88%
Liabilities and Equity 695M USD +79.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.8M USD -6.66%
Net Cash Provided by (Used in) Financing Activities 322M USD +20291%
Net Cash Provided by (Used in) Investing Activities -114M USD -1201%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 52.3M shares +13.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 45M USD +45.2%
Deferred Tax Assets, Gross 52.6M USD +35.2%
Operating Lease, Liability 23.4M USD -5.87%
Depreciation 532K USD +17.4%
Payments to Acquire Property, Plant, and Equipment 197K USD -30.9%
Lessee, Operating Lease, Liability, to be Paid 32.4M USD -9.44%
Property, Plant and Equipment, Gross 9.82M USD +1.2%
Operating Lease, Liability, Current 1.69M USD +15.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.61M USD +3.02%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.51M USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.97M USD -17.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.72M USD +2.99%
Deferred Tax Assets, Operating Loss Carryforwards 18.7M USD +15.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.39M USD +87.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.83M USD +2.99%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 7.65M USD -3.67%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%